Connable Office Inc. held its stake in shares of Mednax, Inc (NYSE:MD) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,349 shares of the company’s stock at the end of the second quarter. Connable Office Inc.’s holdings in Mednax were worth $323,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of MD. Ledyard National Bank increased its position in Mednax by 19.0% in the first quarter. Ledyard National Bank now owns 1,725 shares of the company’s stock worth $120,000 after buying an additional 275 shares during the last quarter. Pacer Advisors Inc. increased its position in Mednax by 3.2% in the first quarter. Pacer Advisors Inc. now owns 1,795 shares of the company’s stock worth $125,000 after buying an additional 55 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its position in Mednax by 870.9% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 2,000 shares of the company’s stock worth $139,000 after buying an additional 1,794 shares during the last quarter. Morgan Dempsey Capital Management LLC increased its position in Mednax by 3.6% in the first quarter. Morgan Dempsey Capital Management LLC now owns 2,270 shares of the company’s stock worth $157,000 after buying an additional 78 shares during the last quarter. Finally, Mn Services Vermogensbeheer B.V. increased its position in Mednax by 4.4% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,428 shares of the company’s stock worth $158,000 after buying an additional 102 shares during the last quarter.

Shares of Mednax, Inc (NYSE MD) opened at 42.10 on Friday. The firm has a market cap of $3.88 billion, a PE ratio of 13.41 and a beta of 0.40. Mednax, Inc has a 12 month low of $41.90 and a 12 month high of $72.13. The company’s 50 day moving average is $54.64 and its 200-day moving average is $61.63.

Mednax (NYSE:MD) last posted its quarterly earnings data on Friday, July 28th. The company reported $0.85 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.81 by $0.04. Mednax had a net margin of 8.78% and a return on equity of 11.89%. The business had revenue of $843 million during the quarter, compared to analysts’ expectations of $849.49 million. During the same quarter in the prior year, the business posted $1.03 earnings per share. Mednax’s revenue was up 9.2% compared to the same quarter last year. Equities research analysts predict that Mednax, Inc will post $3.31 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Connable Office Inc. Has $323,000 Position in Mednax, Inc (NYSE:MD)” was first posted by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/08/11/connable-office-inc-has-323000-position-in-mednax-inc-nysemd.html.

MD has been the subject of a number of analyst reports. Jefferies Group LLC set a $46.00 price objective on shares of Mednax and gave the stock a “hold” rating in a report on Sunday, July 30th. BidaskClub downgraded shares of Mednax from a “sell” rating to a “strong sell” rating in a report on Friday, August 4th. Zacks Investment Research raised shares of Mednax from a “sell” rating to a “hold” rating in a report on Thursday, April 13th. Bank of America Corporation downgraded shares of Mednax from a “buy” rating to an “underperform” rating in a report on Thursday, May 4th. Finally, ValuEngine downgraded shares of Mednax from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $64.00.

In related news, insider Joseph M. Calabro sold 23,327 shares of the company’s stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $55.00, for a total transaction of $1,282,985.00. Following the completion of the sale, the insider now owns 296,379 shares of the company’s stock, valued at $16,300,845. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Md Pascal J. Goldschmidt sold 1,969 shares of the company’s stock in a transaction dated Wednesday, June 14th. The stock was sold at an average price of $57.57, for a total transaction of $113,355.33. Following the sale, the director now directly owns 18,072 shares of the company’s stock, valued at approximately $1,040,405.04. The disclosure for this sale can be found here. Corporate insiders own 2.40% of the company’s stock.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax, Inc (NYSE:MD).

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.